Market Overview

Anpac Bio CEO Speaking on Expert 'Genomics 2.0' Summit Liquid Biopsy Panel

Share:

Dr. Chris
Yu
, Chief Executive Officer (CEO) of international life sciences
corporation, Anpac
Bio-Medical Science Company
, will speak as a global authority on
Liquid Biopsy technology at UBS'
authoritative, "Genomics 2.0 Summit", in Park City, Utah; Thursday,
August 9, 2018 at 11:30 am.

Yu will join other expert panelists, including Chad Robins, Adaptive
Biotechnologies
CEO; and Girish Putcha, Director
of Lab Science, Palmetto's MolDX
and Chief Medical Officer of Freenome;
to discuss the latest advances in "liquid biopsy" research; and its
current and projected future Genomics applications.

Pioneering liquid biopsy technology (beginning research in 2008;
launching Anpac Bio's "Cancer
Differentiation Analysis
" liquid biopsy screenings in 2010), Yu will
share with "Genomics 2.0" attendees how Anpac Bio's proprietary CDA
liquid biopsies have effectively reinvented early cancer screening and
detection.

Comprehensive research validity data from 100,000+ cases processed (to
date), demonstrate CDA diagnostics consistently detects 26+ different
cancers -- with sensitivity and specificity rates of 75%-90% -- usually
identifying the disease at the earliest stages. And it does so without any harmful
side effects in patients; generating far fewer "false positives"; at a
cost, substantially lower than traditional testing (such as imaging);
and generating results within minutes of sample submission.

Yu was invited to speak on the prestigious panel due to CDA's multi-award-winning
and disruptive innovations
such as: multi-cancer screening in a single test;
multi-level/multi-parameter screening of standard blood samples; and
mass, low-cost, high accuracy testing without patient side effects.
Anpac Bio has filed 250+ CDA-related patent applications worldwide – 90+
issued by 20 countries (to date); and projects surpassing 300,000+
liquid biopsy cases in 2018.

"I am honored to speak on such a prestigious liquid biopsy research
panel," states Yu. "Our Anpac Bio team is extremely proud I can report
with authority about liquid biopsy's practical application in the
marketplace; and its ability to transform modern healthcare. Our company
is already doing it! Having processed 100,000 cases, Anpac Bio's
comprehensive ‘Big Data' base confirms we have identified cancer in
thousands of people worldwide; many of which were deemed ‘cancer free'
by traditional screening methods. Anpac Bio's ‘liquid biopsy' technology
is not theoretical or just ‘in the lab'. It's real; and saving lives on
a weekly basis! We look forward to sharing that information at Genomics
2.0."

For further information: AnpacBio.com.

View Comments and Join the Discussion!